Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck (MRK) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Merck (MRK) has demonstrated stronger recent momentum driven by robust Keytruda sales, new product launches, and raised full-year revenue guidance following solid Q2 2026 results.
- Novartis (NVS) experienced significant share price pressure in recent weeks after two late-stage clinical trial setbacks involving del-desiran and pelacarsen.
- Both companies operate in the pharmaceuticals sector with exposure to oncology and other therapeutic areas, though MRK’s pipeline updates have supported relative outperformance compared with broader market benchmarks.
- MRK’s stock has shown greater stability and positive year-to-date returns amid ongoing sector rotation, while NVS faces heightened scrutiny over its M&A strategy and pipeline execution.
- Market sentiment currently favors MRK’s consistency in growth drivers, whereas NVS contends with near-term volatility tied to clinical outcomes.
- Relative performance metrics highlight trade-offs between MRK’s oncology-led expansion and NVS’s established international presence in multiple therapeutic categories.
Introduction
Merck (MRK) and Novartis (NVS) represent two major players in the global pharmaceuticals industry, making them relevant for investors and traders seeking exposure to healthcare innovation, patent-protected therapies, and evolving regulatory landscapes. This comparison examines their recent stock behavior, business fundamentals, and market positioning within the current environment of clinical developments and sector dynamics. Portfolio managers, institutional investors, and active traders monitoring relative performance in large-cap pharmaceuticals may find the analysis useful for assessing diversification opportunities and momentum shifts between these established names.
MRK Overview and Recent Performance
Merck & Co., Inc. (MRK) is a leading U.S.-based pharmaceutical company focused on oncology, vaccines, and animal health. Its flagship product Keytruda continues to drive revenue, with combined sales reaching $8.4 billion in Q2 2026. Recent market activity shows the stock benefiting from FDA approvals, including LIPFENDRA as the first oral PCSK9 inhibitor for hypercholesterolemia, and continued uptake of Winrevair. In recent weeks, the company raised its 2026 revenue outlook to $66.3 billion–$67.3 billion after reporting $16.6 billion in quarterly sales, up 5% year-over-year. These catalysts have supported positive sentiment and contributed to outperformance relative to broader indices in recent periods.
NVS Overview and Recent Performance
Novartis AG (NVS) is a Swiss multinational pharmaceutical company with a diversified portfolio spanning oncology, cardiovascular, and neuroscience. The firm has pursued growth through acquisitions, including assets from Avidity Biosciences. However, recent market activity has been dominated by clinical disappointments. In early September 2026, two Phase 3 trials—HARBOR for del-desiran in myotonic dystrophy type 1 and Lp(a)HORIZON for pelacarsen—failed to meet primary endpoints, triggering sharp share price declines exceeding 13% on a single day. These events have weighed on near-term sentiment and prompted investor calls for governance reviews, contrasting with more stable performance in prior months.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of high-performing AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section, reflecting varied trading styles, strategies, timeframes, and performance statistics. Available bots exhibit ranges of returns, win rates, and drawdown profiles tailored to different risk tolerances and asset classes. The platform enables users to explore these options and identify bots suited to current conditions. Review the full selection on the Trending AI Robots page for detailed metrics.
Head-to-Head Comparison
Merck (MRK) and Novartis (NVS) differ in business model emphasis and recent momentum. MRK derives substantial growth from oncology leadership via Keytruda and new launches, delivering consistent revenue expansion and raised guidance. NVS maintains broader international diversification but has faced pipeline volatility from recent trial outcomes, increasing focus on M&A returns. In terms of risk factors, MRK contends with competitive pressures in oncology, while NVS encounters execution risks following clinical setbacks. Sector exposure remains comparable within healthcare, yet MRK’s recent stability contrasts with NVS’s heightened sensitivity to binary events. Market sentiment reflects these contrasts, with MRK positioned for steadier relative performance amid ongoing product cycles.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent catalysts, and relative positioning, Tickeron’s AI would currently assign a higher probability of favor to Merck (MRK) over Novartis (NVS). Stronger earnings momentum and pipeline approvals provide a more stable foundation compared with the volatility introduced by clinical trial outcomes at NVS. This assessment remains probabilistic and tied to prevailing data rather than forward guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and NVS is a Buy.
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | 10 | |
SMR RATING 1..100 | 79 | 33 | |
PRICE GROWTH RATING 1..100 | 38 | 56 | |
P/E GROWTH RATING 1..100 | 2 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as MRK (11). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is in the same range as MRK (30). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as NVS (56). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (22). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 46% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 44% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 49% |
| MACD ODDS (%) | 2 days ago 48% | 2 days ago 50% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 40% |
| Advances ODDS (%) | 8 days ago 58% | 2 days ago 54% |
| Declines ODDS (%) | 6 days ago 51% | 21 days ago 43% |
| BollingerBands ODDS (%) | N/A | 2 days ago 34% |
| Aroon ODDS (%) | 2 days ago 67% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).
- MRK’s TA Score: 3 bullish, 4 bearish.
- NVS’s TA Score: 4 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -0.54% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.18% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.47%. For the same industry, the average monthly price growth was -4.06%, and the average quarterly price growth was +11.48%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.47% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.